Cargando…
GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models
Preclinical models that reliably recapitulate the immunosuppressive properties of human gliomas are essential to assess immune-based therapies. GL261 murine glioma cells are widely used as a syngeneic animal model of glioma, however, it has become common practice to transfect these cells with lucife...
Autores principales: | Sanchez, Victoria E., Lynes, John P., Walbridge, Stuart, Wang, Xiang, Edwards, Nancy A., Nwankwo, Anthony K., Sur, Hannah P., Dominah, Gifty A., Obungu, Arnold, Adamstein, Nicholas, Dagur, Pradeep K., Maric, Dragan, Munasinghe, Jeeva, Heiss, John D., Nduom, Edjah K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335060/ https://www.ncbi.nlm.nih.gov/pubmed/32620877 http://dx.doi.org/10.1038/s41598-020-67411-w |
Ejemplares similares
-
Author Correction: GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models
por: Sanchez, Victoria E., et al.
Publicado: (2022) -
Current Options and Future Directions in Immune Therapy for Glioblastoma
por: Lynes, John, et al.
Publicado: (2018) -
Biomarkers for immunotherapy for treatment of glioblastoma
por: Lynes, John P, et al.
Publicado: (2020) -
Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells
por: Clark, Aaron J, et al.
Publicado: (2014) -
Variations in attitudes towards stereotactic biopsy of adult diffuse midline glioma patients: a survey of members of the AANS/CNS Tumor Section
por: Lynes, John, et al.
Publicado: (2020)